Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal]
Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D.
The American Society for Pharmacology and Experimental Therapeutics
Published 2018
The American Society for Pharmacology and Experimental Therapeutics
Published 2018
| Publication Date: |
2018-10-09
|
|---|---|
| Publisher: |
The American Society for Pharmacology and Experimental Therapeutics
|
| Print ISSN: |
0022-3565
|
| Electronic ISSN: |
1521-0103
|
| Topics: |
Medicine
|
| Published by: |
| _version_ | 1836399064256610304 |
|---|---|
| autor | Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. |
| beschreibung | Chronic hepatitis is the major cause of liver cirrhosis and portal hypertension. Several factors affect portal pressure, including liver fibrosis, splanchnic vasodilatation, and pathologic angiogenesis. Nucleos(t)ide analogs (NUCs), the oral antiviral agents, effectively attenuate chronic hepatitis B-related liver cirrhosis and portal hypertension via viral suppression and alleviation of hepatitis. On the other hand, NUCs affect tumor necrosis factor (TNF)- α , vascular endothelial growth factor (VEGF), and nitric oxide, which participate in fibrogenesis, vasodilatation, and angiogenesis. However, whether NUCs independently influence liver fibrosis and portal hypertension beyond viral suppression is unknown. This study thus aimed to evaluate the influences of three frequently used NUCs in rats with nonviral cirrhosis. Male Sprague-Dawley rats received common bile duct ligation (CBDL) to induce cholestatic cirrhosis and portal hypertension. The rats were randomly allocated into four groups, treated by mouth with lamivudine (30 mg/kg per day), entecavir (0.09 mg/kg per day), tenofovir (50 mg/kg per day), or distilled water (vehicle control) from the 15th day after CBDL. On the 29th day, liver cirrhosis- and portal hypertension-related parameters were evaluated. The results showed that chronic NUCs treatment did not affect hemodynamic parameters, plasma TNF- α concentration, and hepatic fibrogenesis protein expressions in rats with nonviral cirrhosis. Though the mesenteric VEGF receptor 2 phosphorylation was downregulated in NUCs-treated groups, the splanchnic angiogenesis was not influenced. In conclusion, lamivudine, entecavir, and tenofovir had no additional effects on liver cirrhosis and portal hypertension in rats with nonviral cirrhosis. |
| citation_standardnr | 6342074 |
| datenlieferant | ipn_articles |
| feed_id | 1930 |
| feed_publisher | The American Society for Pharmacology and Experimental Therapeutics |
| feed_publisher_url | http://www.aspet.org/ |
| insertion_date | 2018-10-09 |
| journaleissn | 1521-0103 |
| journalissn | 0022-3565 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | The American Society for Pharmacology and Experimental Therapeutics |
| quelle | Journal of Pharmacology and Experimental Therapeutics |
| relation | http://jpet.aspetjournals.org/cgi/content/short/367/2/260?rss=1 |
| search_space | articles |
| shingle_author_1 | Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. |
| shingle_author_2 | Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. |
| shingle_author_3 | Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. |
| shingle_author_4 | Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. |
| shingle_catch_all_1 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] Chronic hepatitis is the major cause of liver cirrhosis and portal hypertension. Several factors affect portal pressure, including liver fibrosis, splanchnic vasodilatation, and pathologic angiogenesis. Nucleos(t)ide analogs (NUCs), the oral antiviral agents, effectively attenuate chronic hepatitis B-related liver cirrhosis and portal hypertension via viral suppression and alleviation of hepatitis. On the other hand, NUCs affect tumor necrosis factor (TNF)- α , vascular endothelial growth factor (VEGF), and nitric oxide, which participate in fibrogenesis, vasodilatation, and angiogenesis. However, whether NUCs independently influence liver fibrosis and portal hypertension beyond viral suppression is unknown. This study thus aimed to evaluate the influences of three frequently used NUCs in rats with nonviral cirrhosis. Male Sprague-Dawley rats received common bile duct ligation (CBDL) to induce cholestatic cirrhosis and portal hypertension. The rats were randomly allocated into four groups, treated by mouth with lamivudine (30 mg/kg per day), entecavir (0.09 mg/kg per day), tenofovir (50 mg/kg per day), or distilled water (vehicle control) from the 15th day after CBDL. On the 29th day, liver cirrhosis- and portal hypertension-related parameters were evaluated. The results showed that chronic NUCs treatment did not affect hemodynamic parameters, plasma TNF- α concentration, and hepatic fibrogenesis protein expressions in rats with nonviral cirrhosis. Though the mesenteric VEGF receptor 2 phosphorylation was downregulated in NUCs-treated groups, the splanchnic angiogenesis was not influenced. In conclusion, lamivudine, entecavir, and tenofovir had no additional effects on liver cirrhosis and portal hypertension in rats with nonviral cirrhosis. Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. The American Society for Pharmacology and Experimental Therapeutics 0022-3565 00223565 1521-0103 15210103 |
| shingle_catch_all_2 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] Chronic hepatitis is the major cause of liver cirrhosis and portal hypertension. Several factors affect portal pressure, including liver fibrosis, splanchnic vasodilatation, and pathologic angiogenesis. Nucleos(t)ide analogs (NUCs), the oral antiviral agents, effectively attenuate chronic hepatitis B-related liver cirrhosis and portal hypertension via viral suppression and alleviation of hepatitis. On the other hand, NUCs affect tumor necrosis factor (TNF)- α , vascular endothelial growth factor (VEGF), and nitric oxide, which participate in fibrogenesis, vasodilatation, and angiogenesis. However, whether NUCs independently influence liver fibrosis and portal hypertension beyond viral suppression is unknown. This study thus aimed to evaluate the influences of three frequently used NUCs in rats with nonviral cirrhosis. Male Sprague-Dawley rats received common bile duct ligation (CBDL) to induce cholestatic cirrhosis and portal hypertension. The rats were randomly allocated into four groups, treated by mouth with lamivudine (30 mg/kg per day), entecavir (0.09 mg/kg per day), tenofovir (50 mg/kg per day), or distilled water (vehicle control) from the 15th day after CBDL. On the 29th day, liver cirrhosis- and portal hypertension-related parameters were evaluated. The results showed that chronic NUCs treatment did not affect hemodynamic parameters, plasma TNF- α concentration, and hepatic fibrogenesis protein expressions in rats with nonviral cirrhosis. Though the mesenteric VEGF receptor 2 phosphorylation was downregulated in NUCs-treated groups, the splanchnic angiogenesis was not influenced. In conclusion, lamivudine, entecavir, and tenofovir had no additional effects on liver cirrhosis and portal hypertension in rats with nonviral cirrhosis. Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. The American Society for Pharmacology and Experimental Therapeutics 0022-3565 00223565 1521-0103 15210103 |
| shingle_catch_all_3 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] Chronic hepatitis is the major cause of liver cirrhosis and portal hypertension. Several factors affect portal pressure, including liver fibrosis, splanchnic vasodilatation, and pathologic angiogenesis. Nucleos(t)ide analogs (NUCs), the oral antiviral agents, effectively attenuate chronic hepatitis B-related liver cirrhosis and portal hypertension via viral suppression and alleviation of hepatitis. On the other hand, NUCs affect tumor necrosis factor (TNF)- α , vascular endothelial growth factor (VEGF), and nitric oxide, which participate in fibrogenesis, vasodilatation, and angiogenesis. However, whether NUCs independently influence liver fibrosis and portal hypertension beyond viral suppression is unknown. This study thus aimed to evaluate the influences of three frequently used NUCs in rats with nonviral cirrhosis. Male Sprague-Dawley rats received common bile duct ligation (CBDL) to induce cholestatic cirrhosis and portal hypertension. The rats were randomly allocated into four groups, treated by mouth with lamivudine (30 mg/kg per day), entecavir (0.09 mg/kg per day), tenofovir (50 mg/kg per day), or distilled water (vehicle control) from the 15th day after CBDL. On the 29th day, liver cirrhosis- and portal hypertension-related parameters were evaluated. The results showed that chronic NUCs treatment did not affect hemodynamic parameters, plasma TNF- α concentration, and hepatic fibrogenesis protein expressions in rats with nonviral cirrhosis. Though the mesenteric VEGF receptor 2 phosphorylation was downregulated in NUCs-treated groups, the splanchnic angiogenesis was not influenced. In conclusion, lamivudine, entecavir, and tenofovir had no additional effects on liver cirrhosis and portal hypertension in rats with nonviral cirrhosis. Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. The American Society for Pharmacology and Experimental Therapeutics 0022-3565 00223565 1521-0103 15210103 |
| shingle_catch_all_4 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] Chronic hepatitis is the major cause of liver cirrhosis and portal hypertension. Several factors affect portal pressure, including liver fibrosis, splanchnic vasodilatation, and pathologic angiogenesis. Nucleos(t)ide analogs (NUCs), the oral antiviral agents, effectively attenuate chronic hepatitis B-related liver cirrhosis and portal hypertension via viral suppression and alleviation of hepatitis. On the other hand, NUCs affect tumor necrosis factor (TNF)- α , vascular endothelial growth factor (VEGF), and nitric oxide, which participate in fibrogenesis, vasodilatation, and angiogenesis. However, whether NUCs independently influence liver fibrosis and portal hypertension beyond viral suppression is unknown. This study thus aimed to evaluate the influences of three frequently used NUCs in rats with nonviral cirrhosis. Male Sprague-Dawley rats received common bile duct ligation (CBDL) to induce cholestatic cirrhosis and portal hypertension. The rats were randomly allocated into four groups, treated by mouth with lamivudine (30 mg/kg per day), entecavir (0.09 mg/kg per day), tenofovir (50 mg/kg per day), or distilled water (vehicle control) from the 15th day after CBDL. On the 29th day, liver cirrhosis- and portal hypertension-related parameters were evaluated. The results showed that chronic NUCs treatment did not affect hemodynamic parameters, plasma TNF- α concentration, and hepatic fibrogenesis protein expressions in rats with nonviral cirrhosis. Though the mesenteric VEGF receptor 2 phosphorylation was downregulated in NUCs-treated groups, the splanchnic angiogenesis was not influenced. In conclusion, lamivudine, entecavir, and tenofovir had no additional effects on liver cirrhosis and portal hypertension in rats with nonviral cirrhosis. Hsieh, Y.-H., Huang, H.-C., Chang, C.-C., Chuang, C.-L., Lee, F.-Y., Hsu, S.-J., Huang, Y.-H., Hou, M.-C., Lee, S.-D. The American Society for Pharmacology and Experimental Therapeutics 0022-3565 00223565 1521-0103 15210103 |
| shingle_title_1 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] |
| shingle_title_2 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] |
| shingle_title_3 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] |
| shingle_title_4 | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] |
| timestamp | 2025-06-30T23:37:02.019Z |
| titel | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] |
| titel_suche | Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat [Gastrointestinal, Hepatic, Pulmonary, and Renal] |
| topic | WW-YZ |
| uid | ipn_articles_6342074 |